Profile: Depomed Inc (DEPO.BE)
29 May 2017
Depomed, Inc. incorporated on August 7, 1995, is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), CAMBIA (diclofenac potassium for oral solution), Zipsor (diclofenac potassium) and Lazanda (fentanyl).
Its NUCYNTA ER (tapentadol extended release tablets) is a product for the management of pain severe enough to require daily long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults, and its NUCYNTA (tapentadol) is a product for the management of moderate to severe acute pain in adults. Its Gralise (gabapentin) is a once-daily product for the management of postherpetic neuralgia (PHN). Its CAMBIA (diclofenac potassium for oral solution) is a product for the acute treatment of migraine attacks. Its Zipsor (diclofenac potassium) liquid filled capsules are used for the treatment of mild to moderate acute pain. Its Lazanda (fentanyl) nasal spray is a product for the management of breakthrough pain in cancer patients 18 years of age and older, already receiving and tolerant to opioid therapy for their underlying persistent cancer pain.
The Company also has a portfolio of royalty and milestone producing license agreements based on its Acuform gastroretentive drug delivery technology. In collaboration with Ironwood Pharmaceuticals, Inc., the Company offers IW-3718, which is under evaluation for refractory gastroesophageal reflux disease (GERD).
The Company competes with Insys Therapeutics, Inc., Sentynl Therapeutics Inc., Collegium Pharmaceutical, Inc., Mallinckrodt Inc., Endo Pharmaceuticals, Inc., Pfizer, Inc., Arbor Pharmaceuticals and Teva.
7999 Gateway Blvd Ste 300
NEWARK CA 94560-1188
Company Web Links
- BRIEF-Depomed announces corporate governance updates
- BRIEF-Depomed reports Q1 adjusted non-GAAP earnings $0.07/shr
- BRIEF-Depomed announces prepayment of $100 mln of secured debt facility
- BRIEF-Depomed- Cooperation agreement with Starboard Value LP includes standstill commitments by Starboard
- U.S. senator launches probe into five top opioid drugmakers